Wall Street Zen Upgrades Henry Schein to "Strong-Buy"

Analysts cite improved financial performance and positive outlook for the healthcare distribution company.

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Wall Street Zen, a financial research firm, has upgraded its rating on Henry Schein (NASDAQ:HSIC) from "buy" to "strong-buy". The upgrade comes after the company reported better-than-expected financial results for the latest quarter and provided an optimistic outlook for the year ahead.

Why it matters

Henry Schein is a major distributor of healthcare products and services, serving dental, medical, and animal health practitioners. The company's performance is seen as an indicator of broader trends in the healthcare industry. The upgrade from Wall Street Zen suggests increased confidence in Henry Schein's ability to navigate market challenges and capitalize on growth opportunities.

The details

In its report, Wall Street Zen cited Henry Schein's improved financial performance, including a rise in revenue and earnings per share that exceeded analyst expectations. The research firm also noted the company's positive outlook for the fiscal year, with Henry Schein projecting continued growth in key business segments.

  • Henry Schein reported its latest quarterly results on Tuesday, February 24, 2026.
  • Wall Street Zen issued its upgrade report on Saturday, February 28, 2026.

The players

Henry Schein

A leading global distributor of healthcare products and services, primarily serving office-based dental, medical, and animal health practitioners.

Wall Street Zen

A financial research firm that provides analysis and ratings on publicly traded companies.

Got photos? Submit your photos here. ›

What they’re saying

“We are pleased to see Henry Schein's strong performance and are confident in the company's ability to continue delivering value to its customers and shareholders.”

— Wall Street Zen Analyst (Wall Street Zen)

What’s next

Investors will be closely watching Henry Schein's stock price and financial results in the coming quarters to see if the company can maintain its momentum and justify the "strong-buy" rating.

The takeaway

The upgrade from Wall Street Zen underscores the healthcare distribution industry's resilience and Henry Schein's position as a leading player in the market. This positive assessment could attract increased investor interest and drive further growth for the company.